drugset / Trial / NCT01342367

Feasibility of Hormones and Radiation for Intermediate or High Risk Prostate Cancer

NCT01342367

Active not recruiting 74 enrolled University of Chicago
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is see if quality of life is improved in patients receiving oral hormone therapy compared to standard of care. The study will also compare survival rates between patients receiving oral hormone therapy and those receiving standard of care.

Timeline

Start
2010-12-17
Primary completion
2020-05-01
Completion
2026-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Bicalutamide Other / unclassified 50 mg Oral
Subject Dutasteride Small molecule 0.5 mg Oral
Subject Finasteride Small molecule 5 mg Oral

Indications